Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lina M Sego"'
Autor:
Darren R. Feldman, David I. Quinn, Nabil Adra, Costantine Albany, Susan M. Perkins, Kayla Marie Lazzara, Samuel Funt, Christin I. Snow, Nasser H. Hanna, Lina M Sego, Ryan Ashkar, Mohammad Abu Zaid, Lawrence H. Einhorn, Sandra K. Althouse
Publikováno v:
Invest New Drugs
BackgroundCD-30 is highly expressed in some patients with non-seminomatous germ-cell tumors. Brentuximab vedotin is an antibody-drug conjugate directed to CD-30. We report a phase 2 trial of brentuximab vedotin in patients with chemo-refractory GCT.P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24c6e932042918187e57a0afe608b3d2
https://europepmc.org/articles/PMC9534326/
https://europepmc.org/articles/PMC9534326/
Autor:
S Dropcho, Naomi B. Haas, Roberto Pili, Hao Liu, Vivek Narayan, Lina M Sego, Theodore F. Logan, Sandra K. Althouse, Nabil Adra, Nur P. Damayanti, Paul Monk
Publikováno v:
Journal of Clinical Oncology. 38:5064-5064
5064 Background: Immunosuppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) limit the efficacy of immunotherapies. We have previously reported that the HDAC inhibitor entinostat has synergistic antitumor effect in combi
Autor:
Brian A. Costello, Costantine Albany, Sara I Edwards, Eric G. Wolfe, Nina D. Wagner-Johnston, Lina M Sego, Kayla Marie Lazzara, Deirdre R. Pachman, Christin I. Snow, Charles L. Loprinzi, Travis J. Dockter, Nasser H. Hanna, Lawrence H. Einhorn
Publikováno v:
Journal of Clinical Oncology. 37:e23078-e23078
e23078 Background: There are limited patient (pt) reported outcome data regarding CDDP neurotoxicity. Methods: CDDP-induced peripheral neuropathy was evaluated in pts with testicular cancer planning to receive CDDP (20 mg/m2/d for 5 days) for ≥ 3 c